Abstract | BACKGROUND/AIMS: METHODS: Thirty-four patients with acute exacerbation were consecutively treated with LAM /ETV. Their clinical improvements were compared. RESULTS: Among LAM-treated and ETV-treated patients, none showed a reduction of <1 log IU/mL in HBV DNA after 1 or 3 months of treatment. Initial virological response, defined as a reduction of 4 log IU/mL in HBV DNA at 6 months, with LAM and ETV, respectively, was 83.3% and 100%. One LAM patient developed hepatic encephalopathy, but all patients in both groups survived. Twelve months after treatment, 41.6% of 24 LAM group patients switched to another drug or added adefovir to their treatment due to the emergence of LAM-resistant mutants. On the other hand, patients receiving ETV did not need to change drugs. CONCLUSIONS: ETV appears to be as effective as LAM in the treatment of patients with acute exacerbation of chronic hepatitis B. Clinicians should carefully start to treat these patients as soon as possible.
|
Authors | Tatsuo Kanda, Masami Shinozaki, Hidehiro Kamezaki, Shuang Wu, Shingo Nakamoto, Makoto Arai, Keiichi Fujiwara, Nobuaki Goto, Fumio Imazeki, Osamu Yokosuka |
Journal | International journal of medical sciences
(Int J Med Sci)
Vol. 9
Issue 1
Pg. 27-32
( 2012)
ISSN: 1449-1907 [Electronic] Australia |
PMID | 22211086
(Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antiviral Agents
- DNA, Viral
- Reverse Transcriptase Inhibitors
- Lamivudine
- entecavir
- Guanine
- Alanine Transaminase
|
Topics |
- Adult
- Aged
- Alanine Transaminase
(analysis)
- Antiviral Agents
(administration & dosage, therapeutic use)
- DNA, Viral
(drug effects)
- Disease Progression
- Drug Resistance
(genetics)
- Female
- Guanine
(administration & dosage, analogs & derivatives, therapeutic use)
- Hepatitis B virus
(drug effects, genetics)
- Hepatitis B, Chronic
(drug therapy)
- Humans
- Lamivudine
(administration & dosage, therapeutic use)
- Male
- Middle Aged
- Retrospective Studies
- Reverse Transcriptase Inhibitors
(therapeutic use)
|